Plain-English translation of NCT04183699 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
Researchers are testing whether a prostate biopsy can use fewer random samples when combined with MRI-guided targeting. Normally, doctors take many biopsy samples to check for cancer, but this study wants to see if taking fewer samples — while still using MRI to guide them to suspicious areas — can find clinically important prostate cancer just as well. If successful, this could mean shorter, safer procedures for men.
Current prostate biopsies require many samples, which increases procedure time, infection risk, and the chance of finding cancers that wouldn't actually harm a patient. This study aims to streamline the biopsy process to make it safer and more efficient while still catching cancer that matters.
During a single procedure session, you will receive a prostate biopsy guided by MRI to target suspicious areas (4 samples), followed by additional random samples taken from different parts of the prostate (6 samples, then 14 more samples). All samples are carefully labeled and analyzed separately to see which sampling approach best finds clinically important cancer. The entire procedure happens in one session with the same doctor performing all steps.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
Italy